Takeda Pharmaceutical (TAK) Total Current Liabilities (2017 - 2026)

Takeda Pharmaceutical's Total Current Liabilities history runs 10 years deep, the most recent figure standing at $18.1 billion for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 9.92% year-over-year to $18.1 billion in Q1 2026; TTM through Mar 2026 was $18.1 billion, a 9.92% increase from a year earlier, with the FY2026 full-year figure at $18.8 billion, up 14.34% from the prior year.
• Total Current Liabilities climbed to $18.1 billion in Q1 2026 per TAK's latest filing, from $17.0 billion in the prior quarter.
• Across five years, Total Current Liabilities topped out at $18.8 billion in Q1 2023 and bottomed at $13.8 billion in Q4 2024.
• The 5-year median for Total Current Liabilities is $16.4 billion (2023), against an average of $16.4 billion.
• Across the five-year window, Total Current Liabilities retreated 16.81% in 2024 and gained 22.9% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $15.8 billion in 2022, then slipped by 2.49% to $15.4 billion in 2023, then dropped by 10.62% to $13.8 billion in 2024, then rose by 22.9% to $17.0 billion in 2025, then grew by 6.47% to $18.1 billion in 2026.
• Per Business Quant, the three latest TAK Total Current Liabilities figures stand at $18.1 billion (Q1 2026), $17.0 billion (Q4 2025), and $14.5 billion (Q3 2025).